Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07430345 | Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study | PHASE1/PHASE2 | NOT YET_RECRUITING | 48 | — | — | Apr 1, 2026 | Jan 1, 2027 | Feb 23, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| Buprenorphine 0.15 MG | DRUG | given every 15 minutes as needed for numerical pain score 4 or greater for a maximum of three doses |
| Hydromorphone 0.25 mg IV | DRUG | given every 15 minutes as needed for numerical pain score 4 or greater for a maximum of three doses |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 23 | NA | Undisclosed |
| Stryker Corporation | SYK | 4 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | NA | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | — | Undisclosed |
| Cooper Companies, Inc. | COO | 1 | — | Undisclosed |